{"id":"W4412708027","doi":"10.1016/j.esmoop.2025.105506","title":"Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb; Samsung; Genentech; Natera; Seagen; Puma Biotechnology; Pfizer; Incyte; BeiGene; Mersana Therapeutics; Menarini Silicon Biosystems; Astex Pharmaceuticals; Eisai; Jazz Pharmaceuticals; McGill University; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Oncology; Internal medicine; Cancer research; Cancer; Breast cancer; Medicine; Biology; Estrogen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000349191,0.0001790284,0.0003161787,0.00009629208,0.0001763064,0.00006891066,0.0001208581,0.00003355642,0.00008163608],"category_scores_gemma":[0.0001121877,0.0001199266,0.00005063763,0.0002499428,0.00008971299,0.0001956217,0.0000885811,0.0001776511,8.48808e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001769091,"about_ca_system_score_gemma":0.0002856051,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002196479,"about_ca_topic_score_gemma":0.0004624474,"domain_scores_codex":[0.9988737,0.0001181199,0.0002558282,0.0003282414,0.000213402,0.0002107433],"domain_scores_gemma":[0.9991726,0.0003913788,0.0001308483,0.0001531567,0.0001057314,0.00004627962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5492194,0.005599009,0.01207727,0.0007260484,0.001118384,0.0006298953,0.0266762,0.0003106481,0.0005956245,0.00477649,0.0008132534,0.3974578],"study_design_scores_gemma":[0.6247355,0.008687858,0.2934551,0.00965855,0.0009252001,0.0005825554,0.01289976,0.02802855,0.003420574,0.01487372,0.001603217,0.001129409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854577,0.0001204156,0.000566649,0.008226336,0.0001511917,0.004530719,0.0004194619,0.00001619775,0.0005113301],"genre_scores_gemma":[0.9937661,0.000002879363,0.001836583,0.001289813,0.0001521246,0.002642458,0.00008583259,0.00002159037,0.0002026656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3963284,"threshold_uncertainty_score":0.4890463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01736116853606104,"score_gpt":0.3840519532464865,"score_spread":0.3666907847104255,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}